---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-26-000010"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2026-07-01T11:33:29+00:00"
generated_at: "2026-07-01T11:35:04.827451+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# iBio reports single-dose IBIO-610 achieves 98% Activin E inhibition at 4 weeks in obese NHP study

## Summary
- Single dose of IBIO-610 reduced active Activin E by 98% at week 4 and 97% at week 8 vs baseline in obese NHPs.
- When combined with semaglutide, IBIO-610 reduced lean mass loss by 73% versus semaglutide alone.
- Data supports potential for infrequent dosing and fat-selective weight loss while preserving lean mass.
- Full dataset to be presented at EASD Annual Meeting in Milan, September 28 – October 2, 2026.

## SEC filing metadata
- accession: 0001420720-26-000010
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2026-07-01T11:33:29+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000010/0001420720-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000010/ibio-20260701x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-26-000010
- JSON: https://secwatch.observer/filing/0001420720-26-000010.json
- Plain text: https://secwatch.observer/filing/0001420720-26-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.